CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that it plans to publicly offer 6,000,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. In connection with this offering, Altus plans to grant to the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any. All of the shares are being offered by Altus Pharmaceuticals. Merrill Lynch & Co. and Morgan Stanley and Co. are joint book-running managers for the offering. Cowen & Co. and Leerink Swann & Company are co-managers for the offering.
